Skip to main content

Drug Interactions between fexofenadine and vibegron

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

fexofenadine vibegron

Applies to: fexofenadine and vibegron

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with vibegron may increase the plasma concentrations and effects of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter. The exact mechanism for this interaction has not been established. When a single dose of vibegron (100 mg) was administered to healthy volunteers, the peak plasma concentration (Cmax) and systemic exposure (AUC) of the P-gp substrate digoxin increased by 21% and 11%, respectively. The risk of adverse reactions related to these substrates may be increased.

MANAGEMENT: Caution is advised if vibegron is coadministered with substrates of P-gp, particularly sensitive substrates or those with a narrow therapeutic range. The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.

Drug and food interactions

Moderate

fexofenadine food

Applies to: fexofenadine

Consuming large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the levels of fexofenadine in your body. Fexofenadine should be taken with water and refrain from drinking large amounts of grapefruit, orange, or apple juice. This will make it easier for your body to absorb the medication.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer